ACADIA PHARMACEUTICALS INC. Investment Owned, at Fair Value
ACADIA PHARMACEUTICALS INC. (ACAD) had Investment Owned, at Fair Value of $275.60 million as of 2014-03-31, per its 10-Q filed 2014-05-06.
Discontinued › Notes › Financial Services
us-gaap:InvestmentOwnedAtFairValue · last filed 2014-05-06
- 2014-03-31: Investment Owned, at Fair Value $275.60M.
- 2013-12-31: Investment Owned, at Fair Value $174.08M.
- 2013-09-30: Investment Owned, at Fair Value $184.38M.
- 2013-06-30: Investment Owned, at Fair Value $197.94M.
| Period end | Investment Owned, at Fair Value |
|---|---|
| 2014-03-31 | $275.60M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $174.08M 10-Q · filed 2014-05-06 |
| 2013-09-30 | $184.38M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $197.94M 10-Q · filed 2013-08-06 |
| 2012-12-31 | $56.38M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |